ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 69

Fibrofog in Mild and Severe Variants of Fibromyalgia

Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia and memory

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: : A triad of symptoms defines cognitive dysfunction in fibromyalgia known as fibrofog. The set of primary signs are short-term memory loss, a general loss of mental sharpness, and a disturbance in mental clarity.  The stability of this symptom triad is uncertain, in a disorder than is marked by a high degree of symptom variability.  The purpose of this study is to determine if the level of disease intensity needs to be taken into account, when assessing the symptom triad that defines fibrofog.  

Methods: Participants were 61 female patients with a clinical diagnosis of fibromyalgia with a mean age of 50. 7±14.0 years and a mean education of 15.2±2.2 years.    Data on memory loss was collected on a 0-10 point Likert scale with anchor points of no problems to severe problems.  Data on mental sharpness and mental clarity were derived from the 16 item Mental Clutter Scale.  Disease intensity was measured on a 4 point scale ranging from usual symptom status to symptoms severely intensified.

Results: For analytical purposes, disease intensity was collapsed into two categories; low and high disease intensity.  The percentage of high and low disease intensity was 60.7% (37/61) and 39.3% (24/61) respectively.  Comparisons between low and high disease intensity on short term memory, mental sharpness and mental clarity are shown in Table 1.  As can be seen, high disease intensity was related to more severe problems with memory, significant reductions in mental sharpness (p<0.001), and severe disturbances in mental clarity (p<0.001).   The mental clarity score of 3.33 in the low intensity group is approximately one standard deviation below the normative range for fibromyalgia patients with cognitive dysfunction (normative mean: 5.0±2.3).

Conclusion: Patients with fibromyalgia can and do present with mild to severe symptom variants.   These symptom variants are associated with marked differences in the manifestations of the cardinal features of fibrofog.  In the milder symptom variants of fibromyalgia, symptom expression of fibrofog is likely to be muted.  In fibromyalgia, knowledge of disease intensity is likely critical for accurately assessing the presence of fibrofog and needs to be taken into account.

 


Disclosure: R. S. Katz, None; F. Leavitt, None.

To cite this abstract in AMA style:

Katz RS, Leavitt F. Fibrofog in Mild and Severe Variants of Fibromyalgia [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/fibrofog-in-mild-and-severe-variants-of-fibromyalgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibrofog-in-mild-and-severe-variants-of-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology